III ISPOR Congress CAC Chapter

The ISPOR Chapter of Central America and the Caribbean (CAC) held its III Congress in Santo Domingo, Dominican Republic at the Intercontinental Hotel on March 14th and 15th, 2019.

Discussions at the forum focused on the tools offered to decision-makers, considering perspectives such as: efficiency, value for money, and patient centricity.

FIFARMA was represented in this event by Dr. Diego Guarin, Senior Director Evidence and Value Development & HTA Strategy Latin America at EMD Serono and Co-Chair of FIFARMA’s Value and Access to Innovation Working Group. Dr. Guarin participated in the “Claves para la transformación de la sostenibilidad de los sistemas de salud” panel hosted by the Central American Pharmaceutical Laboratories Federation (FEDEFARMA).

According to Dr Guarin: “PAHO’s strategy for Universal Access to Health, recognized financing as a necessary, although not sufficient, condition to reduce inequities and increase the financial protection of the population”.  He continued explaining that “the strategic line of PAHO has 3 priorities:

  • Provide financial protection by eliminating direct payment, which represents a barrier to access
  • Increase public financing of healthcare expenditure to the reference level of 6% of GDP, which implies a commitment by society as a whole to increase the fiscal space reserved for health in terms of new public sources of financing
  • Improve the efficiency of the health system by specifically impacting its financing and organization, aligning payment mechanisms with the objectives of the health system and rationalizing the introduction of new medicines and technologies”.

Even though sustainability in Healthcare Systems represents a challenge in a complex scenario, Dr. Guarin described alternative solutions to empower efficiency and financing.

Risk- Sharing Agreements, added Dr. Guarin quoting an extract by the HTAi Policy Forum 2010, are: “agreements between the producer and a payer/provider to allow access to a health technology subject to specific conditions. These agreements can use a variety of mechanisms to reduce uncertainty about the performance of technology, its adoption or to maximize its effective use or limit its financial impact”.

“At FIFARMA we strongly believe in the value of innovation. Despite the challenging healthcare financing context, it is possible to go beyond budget barriers and stablish innovative agreements which contribute to a sustainable healthcare system all over the region”, highlighted Juan Carlos Trujillo, International Policy and Operations Director at FIFARMA.

Authors:

Diego GuarinEMD Serono Senior Director Evidence and Value Development & HTA Strategy Latin America

Co-Chair of FIFARMA’s Value and Access to Innovation Working

María Alejandra de GuzmanFIFARMA Communications Manager